IDH-wild-type GBMs are highly aggressive brain tumors because of a small subpopulation of cancer stem cells capable of tumor initiation in vivo and multi-lineage differentiation potential to support therapeutic resistance, recurrence, and the progressive growth of tumors (Lathia et al., 2015; Singh et al., 2004; Vescovi et al., 2006). This evidence concerns the gene IDH2 and cancer.